RS50553B - Derivati imidazola kao tafia-inhibitori - Google Patents

Derivati imidazola kao tafia-inhibitori

Info

Publication number
RS50553B
RS50553B RSP-2008/0107A RSP20080107A RS50553B RS 50553 B RS50553 B RS 50553B RS P20080107 A RSP20080107 A RS P20080107A RS 50553 B RS50553 B RS 50553B
Authority
RS
Serbia
Prior art keywords
formula
stands
compound
alkyl
cycloalkyl
Prior art date
Application number
RSP-2008/0107A
Other languages
English (en)
Serbian (sr)
Inventor
Andreas Lindenschmidt
Christopher Kallus
Holger Heitsch
Sven Grueneberg
Hauke Szillat
Original Assignee
Sanofi-Aventis Deutschland Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50553(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi-Aventis Deutschland Gmbh. filed Critical Sanofi-Aventis Deutschland Gmbh.
Publication of RS50553B publication Critical patent/RS50553B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RSP-2008/0107A 2004-04-22 2005-04-07 Derivati imidazola kao tafia-inhibitori RS50553B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (de) 2004-04-22 2004-04-22 Heterocyclylessigsäuren als Inhibitoren von TAFla
PCT/EP2005/003630 WO2005105781A1 (de) 2004-04-22 2005-04-07 Imidazol-derivate als tafia-inhibitoren

Publications (1)

Publication Number Publication Date
RS50553B true RS50553B (sr) 2010-05-07

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2008/0107A RS50553B (sr) 2004-04-22 2005-04-07 Derivati imidazola kao tafia-inhibitori

Country Status (34)

Country Link
EP (2) EP1740569B1 (enExample)
JP (1) JP4939401B2 (enExample)
KR (1) KR101162047B1 (enExample)
CN (1) CN100572376C (enExample)
AR (1) AR053302A1 (enExample)
AT (2) ATE386737T1 (enExample)
AU (1) AU2005238144B2 (enExample)
BR (1) BRPI0510159A (enExample)
CA (1) CA2563401C (enExample)
CR (1) CR8650A (enExample)
CY (1) CY1108087T1 (enExample)
DE (2) DE102004020186A1 (enExample)
DK (1) DK1740569T3 (enExample)
EC (1) ECSP066941A (enExample)
ES (1) ES2299026T3 (enExample)
HR (1) HRP20080099T3 (enExample)
IL (1) IL178672A (enExample)
MA (1) MA28543B1 (enExample)
MY (1) MY140903A (enExample)
NI (1) NI200600217A (enExample)
NO (1) NO20065320L (enExample)
NZ (1) NZ550757A (enExample)
PE (1) PE20060172A1 (enExample)
PL (1) PL1740569T3 (enExample)
PT (1) PT1740569E (enExample)
RS (1) RS50553B (enExample)
RU (1) RU2375356C2 (enExample)
SI (1) SI1740569T1 (enExample)
TN (1) TNSN06341A1 (enExample)
TW (1) TWI359016B (enExample)
UA (1) UA87306C2 (enExample)
UY (1) UY28868A1 (enExample)
WO (1) WO2005105781A1 (enExample)
ZA (1) ZA200607668B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2104497T1 (sl) 2006-12-06 2015-06-30 Sanofi Derivati sulfamida kot inhibitorji TAFIa
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008100459A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Derivatives and analogs of chroman as functionally selective alpha2c adrenoreceptor agonists
CA2693169C (en) 2007-07-19 2016-01-12 Metabolex, Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
US8580777B2 (en) * 2008-06-06 2013-11-12 Sanofi Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa
CA2741783A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having tafia inhibitory activity
RS52963B (sr) * 2009-05-15 2014-02-28 Sanofi Postupak za dobijanje jedinjenja koje je korisno kao inhibitor tafia
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2483281B1 (en) 2009-10-01 2014-06-04 Cymabay Therapeutics, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
BR112012023412A2 (pt) 2010-03-18 2018-05-08 Daiichi Sankyo Company, Limited composto, drogra farmacêutica, inibidor de tafia, promotor de fibrinólise, droga preventiva ou terapêutica, composição farmacêutica, e, uso de um composto.
NZ601658A (en) 2010-03-18 2014-08-29 Daiichi Sankyo Co Ltd Cycloalkyl-substituted imidazole derivative
BR112013011244A2 (pt) * 2010-11-11 2017-10-24 Sanofi Sa processo para a preparação de derivados e ácido 3-(6-amino-piridin-3il)-2-acrílico
US9145385B2 (en) 2011-11-25 2015-09-29 Sanofi Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid
WO2013076177A1 (de) 2011-11-25 2013-05-30 Sanofi Salz von (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl)- propionsäureethylester
US9102657B2 (en) * 2011-11-25 2015-08-11 Sanofi Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
SG11201509144YA (en) 2013-06-10 2015-12-30 Sanofi Sa MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFI<sb>A</sb>, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
EP3437641A4 (en) 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited THERAPEUTIC AGENT AGAINST INFLAMMATORY DARMER DISEASE
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69937307T2 (de) * 1998-12-24 2008-02-07 Astellas Pharma Inc. Imidazol verbindungen und ihre medizinische verwendung
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
WO2003061653A1 (en) 2002-01-22 2003-07-31 Pfizer Limited 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases

Also Published As

Publication number Publication date
AR053302A1 (es) 2007-05-02
ATE523505T1 (de) 2011-09-15
CA2563401A1 (en) 2005-11-10
ECSP066941A (es) 2006-12-20
RU2375356C2 (ru) 2009-12-10
KR101162047B1 (ko) 2012-07-04
TWI359016B (en) 2012-03-01
PE20060172A1 (es) 2006-03-31
EP1740569A1 (de) 2007-01-10
NO20065320L (no) 2007-01-12
ES2299026T3 (es) 2008-05-16
IL178672A (en) 2011-08-31
PL1740569T3 (pl) 2008-07-31
KR20070007346A (ko) 2007-01-15
NZ550757A (en) 2010-06-25
RU2006141246A (ru) 2008-06-10
SI1740569T1 (sl) 2008-06-30
JP4939401B2 (ja) 2012-05-23
CN1950357A (zh) 2007-04-18
CN100572376C (zh) 2009-12-23
JP2007533672A (ja) 2007-11-22
EP1740569B1 (de) 2008-02-20
ATE386737T1 (de) 2008-03-15
UY28868A1 (es) 2005-11-30
PT1740569E (pt) 2008-03-31
CR8650A (es) 2007-12-04
DE102004020186A1 (de) 2005-11-17
IL178672A0 (en) 2007-02-11
ZA200607668B (en) 2008-03-26
CA2563401C (en) 2012-08-07
AU2005238144A1 (en) 2005-11-10
DE502005002927D1 (de) 2008-04-03
AU2005238144B2 (en) 2010-08-26
CY1108087T1 (el) 2014-02-12
MA28543B1 (fr) 2007-04-03
EP1864979B1 (de) 2011-09-07
HRP20080099T3 (en) 2008-03-31
NI200600217A (es) 2008-06-17
HK1101823A1 (zh) 2007-10-26
TNSN06341A1 (en) 2008-02-22
MY140903A (en) 2010-01-29
BRPI0510159A (pt) 2007-10-02
UA87306C2 (en) 2009-07-10
TW200602325A (en) 2006-01-16
EP1864979A1 (de) 2007-12-12
DK1740569T3 (da) 2008-06-02
WO2005105781A1 (de) 2005-11-10

Similar Documents

Publication Publication Date Title
RS50553B (sr) Derivati imidazola kao tafia-inhibitori
KR102240158B1 (ko) 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도
SK22099A3 (en) Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
CZ297544B6 (cs) Substituované N-[(aminoiminomethyl)-fenyl]propylamidy nebo N-[(aminomethyl)fenyl]propylamidy
US8044208B2 (en) Imidazole derivatives as inhibitors of TAFIa
EP2138482A1 (en) Bicyclic heterocyclic compound
NZ575603A (en) ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS
EP2548872A1 (en) Cyclopropanecarboxylic acid derivative
US6750225B2 (en) 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
BRPI0911538A2 (pt) Composição farmacêutica contendo um composto derivado de benzimidazol e uso do composto
ES2603302T3 (es) Imidazopiridazinas como inhibidores de PAR1, su obtención y empleo como medicamento
RU2446160C2 (ru) Тартратные производные для применения в качестве ингибиторов фактора свертывания крови ixa
SA03240142B1 (ar) 2،5- ثنائي مستبدل -3- حمض ميركابتوبينتانويك2,5-disubtitiuted-3- mercaptopentanoic acid
EP3818055B1 (en) Novel bronchodilating hetero-linked amides
CN102250099B (zh) 一类非肽类抗凝血酶抑制剂、其制法以及医药用途
US7863269B2 (en) Imino-imidazo-pyridine derivatives having antithrombotic activity
CN103420984B (zh) 作为前药的达比加群酯衍生物及其制备方法和用途
NZ250001A (en) Alkoxymethyl substituted pyridone biphenyls and medicaments
CA2884767A1 (en) Imidazopyridine derivatives
HK40047621A (en) Bronchodilating hetero-linked amides
HK40047621B (zh) 支气管扩张杂原子连接的酰胺
JPS61197557A (ja) インダン誘導体およびその製法
HK1180340A (en) Cyclopropanecarboxylic acid derivative
MXPA01000511A (en) Piperazinone derivatives and their uses